Gamal El-Din A Abuo-Rahma

Dr. Gamal El-Din A Abuo-Rahma

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MAMohamed Abdel-Aziz
Mohamed Abdel-Aziz
GAGamal El-Din A Abuo-Rahma
Gamal El-Din A Abuo-Rahma
AHAlaa A. Hassan
Alaa A. Hassan

21 August 2020 in RSC Advances
Verified
Journal Article
Open access
PDF file
MMMamdouh F. A. Mohamed
Mamdouh F. A. Mohamed
GAGamal El-Din A Abuo-Rahma
Gamal El-Din A Abuo-Rahma
α,β-Unsaturated chalcone moieties and quinoline scaffolds play an important role in medicinal chemistry, especially in the identification and development of potential anticancer agents.

26 July 2018 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
HEHend A. A. Ezelarab
Hend A. A. Ezelarab
SASamar Hafez Abbas
Samar Hafez Abbas
HHHeba A. Hassan
Heba A. Hassan
GAGamal El-Din A Abuo-Rahma
Gamal El-Din A Abuo-Rahma

1 November 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MAMohamed Abdel-Aziz
Mohamed Abdel-Aziz
SPSo-Eun Park
So-Eun Park
GAGamal El-Din A Abuo-Rahma
Gamal El-Din A Abuo-Rahma
MSMohamed A. Sayed
Mohamed A. Sayed
YKYoungjoo Kwon
Youngjoo Kwon

1 January 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ABAmr K.A. Bass
Amr K.A. Bass
mona said elzoghbimona said elzoghbi
mona said elzoghbi
ENEl-Shimaa M. Nageeb
El-Shimaa M. Nageeb
MMMamdouh F. A. Mohamed
Mamdouh F. A. Mohamed
MBMohamed Badr
Mohamed Badr
GAGamal El-Din A Abuo-Rahma
Gamal El-Din A Abuo-Rahma

11 May 2022 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
Hamada HashemHamada Hashem
Hamada Hashem
AEAmer Ali Abd El-Hafeez
Amer Ali Abd El-Hafeez
KEKareem Ebeid
Kareem Ebeid
AMAml I. Mekkawy
Aml I. Mekkawy
MAMohammed A. S. Abourehab
Mohammed A. S. Abourehab
SASamar Hafez Abbas
Samar Hafez Abbas
A series of novel 1,2,3-triazole-linked ciprofloxacin-chalcones 4a-j were synthesised as potential anticancer agents. Hybrids 4a-j exhibited remarkable anti-proliferative activity against colon cancer cells. Compounds 4a-j displayed IC50s ranged from 2.53-8.67 µM, 8.67–62.47 µM, and 4.19–24.37 µM for HCT116, HT29, and Caco-2 cells; respectively, whereas the doxorubicin, showed IC50 values of 1.22, 0.88, and 4.15 µM. Compounds 4a, 4b, 4e, 4i, and 4j were the most potent against HCT116 with IC50 values of 3.57, 4.81, 4.32, 4.87, and 2.53 µM, respectively, compared to doxorubicin (IC50 = 1.22 µM). Also, hybrids 4a, 4b, 4e, 4i, and 4j exhibited remarkable inhibitory activities against topoisomerase I, II, and tubulin polymerisation. They increased the protein expression level of γH2AX, indicating DNA damage, and arrested HCT116 in G2/M phase, possibly through the ATR/CHK1/Cdc25C pathway. Thus, the novel ciprofloxacin hybrids could be exploited as potential leads for further investigation as novel anticancer medicines to fight colorectal carcinoma. Graphical Abstract